6 recruiting, 2 active not recruiting, 1 terminated. 9 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Recruiting 6, Active not recruiting 2, Terminated 1 |
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
Follow relatlimab: new trials by email Literature Review of relatlimab trials Research Report on relatlimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide) - Melanoma (Skin Cancer), Melanoma Stage IIIB-IV | Phase 2 / Phase 3 | Recruiting | Linnaeus Therapeutics, Inc. | 135 | 2025-08-06 | 2026-04-22 |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma IMA203, nivolumab plus relatlimab, lifileucel - Melanoma, Cutaneous Malignant, Mucosal Melanoma | Phase 3 | Recruiting | Immatics US, Inc. | 450 | 2025-01-14 | 2026-10-30 |
| A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% Nivolumab, Relatlimab, Pembrolizumab - Non-small Cell Lung Cancer | Phase 3 | Recruiting | Bristol-Myers Squibb | 1000 | 2024-10-07 | 2026-10-23 |
| VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab - Advanced Melanoma | Phase 3 | Recruiting | Replimune, Inc. | 400 | 2024-07-11 | 2026-07-15 |
| IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) Brenetafusp, Nivolumab, Nivolumab + Relatlimab - Advanced Melanoma | Phase 3 | Recruiting | Immunocore Ltd | 680 | 2024-06-05 | 2026-02-25 |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography - Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 992 | 2024-02-02 | 2026-11-06 |
| A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma Nivolumab + Relatlimab, rHuPH20 - Melanoma | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 579 | 2023-03-06 | 2026-08-26 |
| A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination - Melanoma | Phase 3 | Terminated | Bristol-Myers Squibb | 1093 | 2021-10-19 | 2026-01-08 |
| A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma Relatlimab, Nivolumab - Melanoma | Phase 2 / Phase 3 | Active not recruiting | Bristol-Myers Squibb | 714 | 2018-04-11 | 2025-09-09 |
Melanoma (4) · Carcinoma, Non-Small-Cell Lung (1) · Melanoma, Cutaneous Malignant (1) · Neoplasms (1)
Bristol-Myers Squibb (4) · Immatics US, Inc. (1) · Immunocore Ltd (1) · Linnaeus Therapeutics, Inc. (1) · National Cancer Institute (NCI) (1) · Replimune, Inc. (1)
United States (9) · Canada (7) · France (7) · Germany (7) · United Kingdom (7) · Spain (6) · Australia (5) · Austria (5) · Belgium (5) · Brazil (5) · Italy (5) · Poland (5) · Argentina (4) · Chile (4) · Denmark (4)
Cedrik Britten, M.D. (1) · Jeannie Hou, MD (1) · Matthew D Galsky (1)
PMID 34986285, PMID 36628573, PMID 37167764, PMID 38320023, PMID 39671533, PMID 40513285, PMID 40940136, PMID 41109920, PMID 41811823, PMID 42770835
2023 (1), U10CA180821 (1)